Nrf2^−/−donor T cells induced less GVHD mortality and morbidity. (A-C) Lethally irradiated BALB/c recipients that received WT B6 TCD BM alone or with 0.5 × 10⁶ B6 WT or Nrf2^−/− T cells were monitored daily for Kaplan-Meier survival analysis (A) and weekly for GVHD clinical scores (B) and weight loss (C). Data represent the mean ± standard error of the mean from 3 independent experiments (BM, n = 14; BM + WT T, n = 29; BM + Nrf2^−/− T, n = 30). Lethally irradiated LP recipients that received WT B6 TCD BM alone or with 2 × 10⁶ B6 WT or Nrf2^−/− T cells were monitored daily for survival (D) and weekly for GVHD clinical scores (E) and weight loss (F). Data represent the mean ± standard error of the mean from 3 independent experiments (n = 6 in BM group, n = 12 each in BM WT T and Nrf2^−/− T groups). ***P < .005.